Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials.

Cuzick, Jack; Brentnall, Adam R.; Segal, Corrinne V.; Šestak, Ivana; Kealy, Roseann; Howell, Anthony; Powles, Trevor J.; Orr, Nicholas; Dowsett, Mitchell

doi:10.1200/jco.2014.32.15_suppl.1519

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, Cuzick et al evaluated a panel of 15 SNIPs and found that they are useful for refining risk estimates in women at high risk of developing breast cancer. 52 …”

Section: Discussionmentioning

confidence: 99%

Preventative therapies for healthy women at high risk of breast cancer

Šestak¹

2014

CMAR

Self Cite

View full text Add to dashboard Cite

Tamoxifen has been shown to reduce the risk of developing estrogen receptor (ER)-positive breast cancer by at least 50%, in both pre- and postmenopausal women. The current challenge is to find new agents with fewer side effects and to find agents that are specifically suitable for premenopausal women with ER-negative breast cancer. Other selective estrogen receptor modulators (SERMs), such as raloxifene, arzoxifene, and lasofoxifene, have been shown to reduce the incidence of breast cancer by 50%–80%. SERMs are interesting agents for the prevention of breast cancer, but longer follow-up is needed for some of them for a complete risk–benefit profile of these drugs. Aromatase inhibitors have emerged as new drugs in the prevention setting for postmenopausal women. In the Mammary Prevention 3 (MAP3) trial, a 65% reduction in invasive breast cancer with exemestane was observed, and the Breast Cancer Intervention Study-II trial, which compared anastrozole with placebo, reported a 60% reduction in those cancers. Although SERMs and aromatase inhibitors have been proven to be excellent agents in the preventive setting specifically for postmenopausal women and ER-positive breast cancer, newer agents have to be found specifically for ER-negative breast cancers, which mostly occur in premenopausal women.

show abstract

“…In a recent study, Cuzick et al evaluated a panel of 15 SNIPs and found that they are useful for refining risk estimates in women at high risk of developing breast cancer. 52 …”

Section: Discussionmentioning

confidence: 99%